Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank cut its stake in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 78.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 25,880 shares of the biopharmaceutical company's stock after selling 92,157 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Dynavax Technologies were worth $288,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of DVAX. Millennium Management LLC acquired a new position in shares of Dynavax Technologies in the 2nd quarter valued at about $17,615,000. Great Point Partners LLC lifted its holdings in shares of Dynavax Technologies by 87.7% during the 2nd quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company's stock valued at $26,660,000 after acquiring an additional 1,109,080 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in Dynavax Technologies during the 3rd quarter worth $8,291,000. Mizuho Markets Americas LLC grew its stake in shares of Dynavax Technologies by 37.9% in the second quarter. Mizuho Markets Americas LLC now owns 1,175,107 shares of the biopharmaceutical company's stock valued at $13,196,000 after buying an additional 323,050 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Dynavax Technologies during the 2nd quarter valued at about $3,144,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Performance

Shares of DVAX stock traded down $0.01 on Monday, hitting $12.84. 859,962 shares of the stock traded hands, compared to its average volume of 2,132,430. The company has a market capitalization of $1.69 billion, a PE ratio of 98.78 and a beta of 1.33. The company's fifty day moving average is $11.88 and its 200 day moving average is $11.44. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $15.01.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and issued a $29.00 price objective on shares of Dynavax Technologies in a research report on Friday, November 8th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.